Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access


IJHSR. 2014; 4(2): 68-72

Incidence of Hypoglycemia and Other Side Effects in Patients of Type 2 Diabetes Mellitus Treated with Glimepiride versus Glibenclamide.

Meenu Rani, Shailesh Yadav, Seema Choudhary, Seema Sharma, Surya Mani Pandey.

Background: Sulfonylureas were among the first oral antihyperglycemic agents developed, but patients on a sulfonylureas experience hypoglycemia. Severe hypoglycemia was a potentially life-threatening condition. Objective: The aim of the study was to compare the frequency of hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Material &Methods: Total 50 patients were included in the study. These patients were divided in group I & II. Group I (n=25): Patients were given Tab. Glibenclamide. Group II (n=25): Patients were given Tab. Glimepiride for 24 weeks. Results: Patients with glibenclamide experienced hypoglycemia (12%) and weight gain (4%) as the main adverse effects while patients with glimepiride had no such adverse effects. Conclusion: In people with type 2 diabetes, glimepiride was associated with fewer episodes of hypoglycemia than glibenclamide.

Key words: Type 2 diabetes mellitus, glimepiride, glibenclamide, hypoglycemia, sulfonylureas.

Share this Article

Journal of Apitherapy


ScopeMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons